These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7995050)

  • 1. Clonogenic assays for gynecologic malignancies. Methodology and results. EORTC Preclinical Therapeutic Models Groups (PTMG).
    Aapro MS
    Contrib Gynecol Obstet; 1994; 19():24-9. PubMed ID: 7995050
    [No Abstract]   [Full Text] [Related]  

  • 2. Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer.
    Köchli OR; Sevin BU; Averette HE; Haller U
    Contrib Gynecol Obstet; 1994; 19():12-23. PubMed ID: 7995043
    [No Abstract]   [Full Text] [Related]  

  • 3. Multi-center collaborative in vitro studies using a human cancer cell line: the EORTC Preclinical Therapeutic Models Group experience.
    Eliason J
    Stem Cells; 1993 Nov; 11(6):519-27. PubMed ID: 8111311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fluorescent cytoprint assay in gynecological malignancies and breast cancer. Methodology and results.
    Blackman KE; Fingert HJ; Fuller AF; Meitner PA
    Contrib Gynecol Obstet; 1994; 19():53-63. PubMed ID: 7995053
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term assay (radiolabeled DNA-precursor uptake method) in gynecologic malignancies. Methodology and results.
    Petru E; Kaufmann M
    Contrib Gynecol Obstet; 1994; 19():30-8. PubMed ID: 7995051
    [No Abstract]   [Full Text] [Related]  

  • 6. ATP-cell viability assay methodology in both fresh gynecologic tumors and cell lines.
    Köchli OR; Perras JP; Sevin BU
    Contrib Gynecol Obstet; 1994; 19():108-21. PubMed ID: 7995042
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.
    Kendrick JE; Estes JM; Straughn JM; Alvarez RD; Buchsbaum DJ
    Gynecol Oncol; 2007 Sep; 106(3):614-21. PubMed ID: 17602728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo chemosensitivity test models for gynecologic malignancies. Methodology and results.
    Kleine W
    Contrib Gynecol Obstet; 1994; 19():76-81. PubMed ID: 7995055
    [No Abstract]   [Full Text] [Related]  

  • 9. Current status and future directions of chemosensitivity testing.
    Sevin BU; Perras JP; Köchli OR
    Contrib Gynecol Obstet; 1994; 19():179-94. PubMed ID: 7995049
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chemotherapy of malignant gynecologic neoplasms].
    Huber R; Lau HU
    Zentralbl Gynakol; 1970 Jul; 92(30):966-70. PubMed ID: 5477142
    [No Abstract]   [Full Text] [Related]  

  • 11. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
    Sládek NE; Kollander R; Sreerama L; Kiang DT
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular targeting therapy for gynecologic cancer].
    Hatae M; Nakamura T; Onishi Y; Yamamoto F
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):233-237. PubMed ID: 18372513
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective assessment of quality of life of female cancer patients.
    Greimel E; Thiel I; Peintinger F; Cegnar I; Pongratz E
    Gynecol Oncol; 2002 Apr; 85(1):140-7. PubMed ID: 11925134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes in the management of gynecologic malignancies.
    Markman M
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):219-26. PubMed ID: 18279063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of specialized nursing for patients with breast cancer and other gynecologic cancers: a prospective, longitudinal, two-arm pilot study in Switzerland].
    Bartholomeyczik S; Schnell M; Aebi S
    Pflege; 2008 Oct; 21(5):353-4. PubMed ID: 18850539
    [No Abstract]   [Full Text] [Related]  

  • 16. [Epidemiological and histological aspects of gynecologic and breast cancer in the pathology department of Niamey's Health Faculty, Niger].
    Nayama M; Nouhou H; Souna-Madougou K; Idi N; Garba M; Tahirou A; Touré A
    Mali Med; 2006; 21(3):43-9. PubMed ID: 19435008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gynecologic pathology.
    Curr Opin Obstet Gynecol; 1990 Jun; 2(3):491-508. PubMed ID: 2102344
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple gene signatures aim to qualify risk in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2005 Mar; 97(5):332. PubMed ID: 15741566
    [No Abstract]   [Full Text] [Related]  

  • 19. New anticancer agents: in vitro and in vivo evaluation.
    Zips D; Thames HD; Baumann M
    In Vivo; 2005; 19(1):1-7. PubMed ID: 15796152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial and error: prognostic gene signature study design altered.
    Tuma RS
    J Natl Cancer Inst; 2005 Mar; 97(5):331-3. PubMed ID: 15741565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.